CLINUVEL provides update on SCENESSE FDA filing
Filed with ASX · · 3 pages · English
Clinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- Preliminary Final Report
- Amended Appendix 4C - quarterly
- NICE England Update on SCENESSE
- CLINUVEL reaches agreement on German SCENESSE pricing
- CLINUVEL agrees with FDA on New Drug Application timelines
Later from Clinuvel Pharmaceuticals
- Preliminary assessment received from NICE
- CLINUVEL hosts European EPP Expert Meeting
- CLINUVEL to take 100% ownership of VALLAURIX joint venture
- CLINUVEL Regulatory Update
- NICE maintains position not to recommend SCENESSE
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals